Skip to main content

Table 2 Change in absolute CST values from baseline to Week 12/EoT CIRC-values (FAS)

From: Primary outcomes of the VIDI study: phase 2, double-masked, randomized, active-controlled study of ASP8232 for diabetic macular edema

 

ASP8232 (n = 32)

ASP8232/ranibizumab (n = 32)

Ranibizumab (n = 31)

Baseline, μm

535.8 (117.9)

511.8 (103.9)

501.6 (105.5)

Week 12 (EoT), μm

530.3 (127.4)

374.0 (105.6)

378.6 (107.5)

Change from baseline at EoT, μm

− 5.5 (119.7)

− 137.8 (142.5)

− 123.1 (112.3)

  1. Data are presented as mean (SD)
  2. CIRC central imaging reading center, CST central subfield thickness, EoT end of treatment, FAS full analysis set